Hikma Pharmaceuticals develops, manufactures and markets generic and specialty medicines, with particular strength in sterile injectables and branded generics. It serves hospitals, pharmacies and healthcare systems primarily in the United States, the Middle East and North Africa, and Europe. Differentiating factors include a large injectables manufacturing platform and deep commercial reach in MENA markets alongside a significant U.S. generics franchise.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 2,517 | — | 188 | — |
| 2023 | 2,875 | 14.2% | 190 | 1.1% |
| 2024 | 3,127 | 8.8% | 359 | 89% |
| 2025 | 3,349 | 7.1% | 402 | 12% |
All markets — KeepWinning global stock screener
Other companies on London Stock Exchange: Entain Plc (ENT), The Berkeley Group Holdings plc (BKG), RIT Capital Partners Ord (RCP), City of London Ord (CTY), Templeton Emerging Mkts Invmt Tr TEMIT (TEM), Inchcape plc (INCH)